S J Bae1, S H Lee2, S H Ahn3, H-M Kim2, B-J Kim2, J-M Koh4. 1. Health Promotion Center, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro 43 gil, Ulsan, Seoul, 05505, South Korea. 2. Division of Endocrinology and Metabolism, Asan Medical Center, University of Ulsan College of Medicine, 88, Olympic-Ro 43-Gil, Songpa-gu, Seoul, 05505, South Korea. 3. Department of Endocrinology, Inha University School of Medicine, 27 Inhang-ro, Jung-Gu, Songpa-gu, Incheon, 22332, South Korea. 4. Division of Endocrinology and Metabolism, Asan Medical Center, University of Ulsan College of Medicine, 88, Olympic-Ro 43-Gil, Songpa-gu, Seoul, 05505, South Korea. jmkoh@amc.seoul.kr.
Abstract
UNLABELLED: A high level of circulating sphingosine-1-phosphate (S1P) is associated with a high incidence of osteoporotic fracture and a high rate of an insufficient response to bisphosphonate therapy. INTRODUCTION: Sphingosine-1-phosphate (S1P) is a significant regulator of bone metabolism. Recently, we found that a high plasma S1P level is associated with low bone mineral density (BMD), high levels of bone resorption markers (BRMs), and a high risk of prevalent vertebral fracture in postmenopausal women. We investigated the possibility that S1P is a predictor of incident fracture. METHODS: A total of 248 postmenopausal women participated in this longitudinal study and were followed up for a mean duration of 3.5 years (untreated [n = 76] or treated with bisphosphonate or hormone replacement therapy [n = 172]). The baseline plasma S1P level and prevalent and incident fracture occurrence were assessed. RESULTS: A high S1P level was significantly associated with a higher rate of prevalent fracture after adjusting for femoral neck (FN) BMD, BRM, and potential confounders (odds ratio = 2.05; 95 % confidence interval [CI] = 1.03-4.00). Incident fractures occurred more frequently in the highest S1P tertile (T3) than in the lower two tertiles (T1-2) after adjusting for confounders, including baseline FN BMD, prevalent fracture, antiosteoporotic medication, annualized changes in FN BMD, BRM, and potential confounders (hazard ratio = 5.52; 95 % CI = 1.04-56.54). Insufficient response to bisphosphonate therapy occurred more frequently in T3 than T1-2 (odds ratio = 4.43; 95 % CI = 1.02-21.25). CONCLUSIONS: The plasma S1P level may be a potential predictor of fracture occurrence and an insufficient response to bisphosphonate therapy in postmenopausal women.
UNLABELLED: A high level of circulating sphingosine-1-phosphate (S1P) is associated with a high incidence of osteoporotic fracture and a high rate of an insufficient response to bisphosphonate therapy. INTRODUCTION:Sphingosine-1-phosphate (S1P) is a significant regulator of bone metabolism. Recently, we found that a high plasma S1P level is associated with low bone mineral density (BMD), high levels of bone resorption markers (BRMs), and a high risk of prevalent vertebral fracture in postmenopausal women. We investigated the possibility that S1P is a predictor of incident fracture. METHODS: A total of 248 postmenopausal women participated in this longitudinal study and were followed up for a mean duration of 3.5 years (untreated [n = 76] or treated with bisphosphonate or hormone replacement therapy [n = 172]). The baseline plasma S1P level and prevalent and incident fracture occurrence were assessed. RESULTS: A high S1P level was significantly associated with a higher rate of prevalent fracture after adjusting for femoral neck (FN) BMD, BRM, and potential confounders (odds ratio = 2.05; 95 % confidence interval [CI] = 1.03-4.00). Incident fractures occurred more frequently in the highest S1P tertile (T3) than in the lower two tertiles (T1-2) after adjusting for confounders, including baseline FN BMD, prevalent fracture, antiosteoporotic medication, annualized changes in FN BMD, BRM, and potential confounders (hazard ratio = 5.52; 95 % CI = 1.04-56.54). Insufficient response to bisphosphonate therapy occurred more frequently in T3 than T1-2 (odds ratio = 4.43; 95 % CI = 1.02-21.25). CONCLUSIONS: The plasma S1P level may be a potential predictor of fracture occurrence and an insufficient response to bisphosphonate therapy in postmenopausal women.
Authors: Richard Eastell; Rosemary A Hannon; Patrick Garnero; Michael J Campbell; Pierre D Delmas Journal: J Bone Miner Res Date: 2007-11 Impact factor: 6.741
Authors: Nelson B Watts; John P Bilezikian; Pauline M Camacho; Susan L Greenspan; Steven T Harris; Stephen F Hodgson; Michael Kleerekoper; Marjorie M Luckey; Michael R McClung; Rachel Pessah Pollack; Steven M Petak Journal: Endocr Pract Date: 2010 Nov-Dec Impact factor: 3.443
Authors: Kerrie M Sanders; Geoffrey C Nicholson; Jennifer J Watts; Julie A Pasco; Margaret J Henry; Mark A Kotowicz; Ego Seeman Journal: Bone Date: 2006-02-28 Impact factor: 4.398
Authors: Teresa A Hillier; Jane A Cauley; Joanne H Rizzo; Kathryn L Pedula; Kristine E Ensrud; Douglas C Bauer; Li-Yung Lui; Kimberly K Vesco; Dennis M Black; Meghan G Donaldson; Erin S Leblanc; Steven R Cummings Journal: J Bone Miner Res Date: 2011-08 Impact factor: 6.741
Authors: Ethel S Siris; Ya-Ting Chen; Thomas A Abbott; Elizabeth Barrett-Connor; Paul D Miller; Lois E Wehren; Marc L Berger Journal: Arch Intern Med Date: 2004-05-24
Authors: Justus M Grewe; Paul-Richard Knapstein; Antonia Donat; Shan Jiang; Daniel J Smit; Weixin Xie; Johannes Keller Journal: Bone Res Date: 2022-04-08 Impact factor: 13.567
Authors: Mohammed-Salleh M Ardawi; Abdulrahim A Rouzi; Nawal S Al-Senani; Mohammed H Qari; Ayman Z Elsamanoudy; Shaker A Mousa Journal: J Bone Metab Date: 2018-05-31